Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × aflutinib × Clear all

Phase

Status

Recruiting 18 Not yet recruiting 12 Unknown 8 Active not recruiting 5 Terminated 3 Completed 2 Withdrawn 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

Cyclophosphamide 100 Radiotherapy 98 Cisplatin 96 pembrolizumab 89 Paclitaxel 73 Carboplatin 71 Nivolumab 67 Gemcitabine 67 Magnetic Resonance Spectroscopy 64 Fluorouracil 63 Dexamethasone 57 Bevacizumab 56 Radiosurgery 52 Docetaxel 51 Rituximab 48 Oxaliplatin 47 Leucovorin 47 fludarabine 44 Capecitabine 44 Biopsy 44 Doxorubicin 37 Etoposide 34 Drug Therapy 34 Cytarabine 34 durvalumab 33 Radiation 33 fludarabine phosphate 32 Lenalidomide 32 Pemetrexed 31 Specimen Handling 30

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04958967 2025-03-14

Phase Ib Study of FURMONERTINIB in Patients with NSCLC Having Exon 20 Insertion Mutation

Allist Pharmaceuticals, Inc.

Phase 1 Withdrawn

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡